Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BHE202218

HIF-PHs inhibitor for CKD and Renal anemia

BLA Filing
  • Project profile
    Project name: HIF-PHs inhibitor for CKD and Renal anemia
    Indications: CKD and Renal anemia
    Research phase: Phase 1
    Cooperation demands: License-out or co-development of the global right (except for China)
  • Highlights

    1. Hugh Market.

    (1) CKD is a major public health problem across the world. India: 145m (17.2%), US: 42m (16.98%), JP: 16m (15.58%) people have CKD.

    (2) 90% of EPO, a key factor for erythropoiesis, is made in kidney. Kidney damage leads to EPO deficiency and releases inflammatory factors that inhibit EPO secretion. Inflammation increases hepcidin which inhibits iron absorption and inhibits iron transport to the liver and spleen, leading to reduction of serum iron and finally reduction of HGB. Therefore 60%-80% of CKD patients combine with renal anemia.

    Clear MOA

    2. Unmeet needs with current therapy

    Clear MOA

    (1) rEPO+Chalybeate is current strategy for renal anemia. However, this therapy is mainly used for the treatment of dialysis patients and patients who are about to dialysis (CKD stage 5, taking up only 2.3% of CKD patients), and many non-dialysis patients (CKD stage 3-4, 71.8% of CKD patients) are lack of efficient therapies.

    (2) Severe cardiovascular adverse reactions (hypertension, stroke) of rEPO with FDA black boxing warning. Poor response to rEPO therapy for 20% of patients with chronic inflammation.

    (3) The expensive price and inconvenient administrate route of biologics.

    3. HIF-PHs inhibitor is a potent solution for renal anemia.

    Clear MOA

    (1) The asset prevents HIF-1α degradation from HIF-PH enzymes, simulating the affair in hypoxia, which promotes EPO mRNA transcription and restore EPO secretion.

    (2) HIF-PHs inhibition is thought to be a potent solution. Several HIF-PHs inhibitors have been approved in JP, India, AU, and China.

    (3) This strategy not only work for renal anemia, but also have a potential to extend chemotherapy anemia and myelodysplastic syndrome (MDS) related anemia indications, which remains a much larger market size.

    4. An effective PHD1/2/3 inhibitor.

    The asset inhibits PHD1/2/3 activity at nanomolar level, slightly better than competitor FG-4592.

    5. Great in vitro activity.

    The asset is more effective than FG-4592 on inhibition of EPO secretion by inflammatory factors in Hep3B.

    6. Excellent in vivo efficacy.

    (1) The asset increased RBC and Hb in a dose-dependent manner in normal cynomolgus monkeys.

    (2) The asset can improve the HGB level of model rats in a dose-dependent manner and no drug accumulation was observed after repeated administration.

    7. Good safety in phase I trial.

    (1) Plasma EPO reached maximum concentration 10-12 hour after dosing. And there was no accumulation of plasma EPO after repeated administration.

    (2) After repeated administration of asset (40, 70, 100 mg), the reticulocyte count was significantly increased with the decrement of the hepcidin level, indicating that asset can effectively promote hematopoiesis and regulate iron metabolism.

    (3) No severe or serious AEs were observed in this study. The incidence of adverse events was not significantly associated with dose escalation, indicating that asset is safe in healthy subjects.

  • Project Introduction

    1. Asset type: HIF-PHs inhibitor

    2. Indication: CKD and Renal anemia

    3. Modality: Small molecular, FIC

    4. Patent: Applicated in 2015

    5. Research phase: Phase 1

    6. Cooperation demands: License-out or co-development of the global right (except for China)

    7. Research progress:

    (1) Phase 1 trials Ia is completed and patent has been applicated;
    (2) Good DMPK and safety properties in preclinical study;
    (3) Safety better than FG-4592;
    (4) Potentially extend chemotherapy anemia and myelodysplastic syndrome (MDS) related anemia indications.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message